An interventional study of D-STORM Resistance Training Programme and usual care in Type 2 Diabetes Mellitus (T2DM), Sarcopenia and Insulin Resistance, sponsored by Universiti Teknologi Mara. Not yet recruiting at 1 site in Malaysia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Universiti Teknologi Mara · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 170 studies in Diabetes Mellitus, Type 2 with a site in Malaysia — 19 open to participants now, 19 under way, 6 of them phase 3. Diabetes Mellitus, Type 2 · Malaysia.
Among the 170 studies in Diabetes Mellitus, Type 2 with a site in Malaysia, this one is the 126th largest by planned enrollment of the 149 interventional ones that give a count, is the only one that started in 2027, is one of 39 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 163rd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →19 of the 170 studies in Diabetes Mellitus, Type 2 with a site in Malaysia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Malaysia, China, Hong Kong and 2 more countries
Ages 18+
Novo Nordisk A/S · Sites in Malaysia, United States, Argentina and 7 more countries
Ages 10–18
AstraZeneca · Sites in Malaysia, United States, Australia and 10 more countries
Ages 18+
AstraZeneca · Sites in Malaysia, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Malaysia, United States, Bulgaria and 13 more countries
Ages 18+
A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
170 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 86 · Phase 4 16
First in 2001; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 370 across the 149 interventional studies, 1,122 across the 21 observational. Of the 141 that completed or were terminated, 68 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 170 have an industry lead sponsor. The 10 most frequent:
Universiti Teknologi Mara is the lead sponsor of 27 studies on the registry; 9 are open to participants now.
Universiti Teknologi Mara has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Malaysia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07877948BREGO Life SciencesComparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing | 2027-01-30 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
| NCT07664501Universiti Teknologi MaraThe Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM) | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 170 studies in Diabetes Mellitus, Type 2 with a site in Malaysia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Type 2 diabetes is associated with progressive loss of muscle mass, which worsens blood sugar control and increases the risk of heart disease and disability. Resistance training (weight training) has been shown to build muscle and improve blood sugar levels, but most existing programmes use high intensities that are difficult for older or inactive people with diabetes to sustain.
This study tests a new resistance training programme called D-STORM (Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population), which uses a lower, more manageable training load designed to be safe, tolerable, and effective for adults with Type 2 diabetes who are not on insulin.
Participants will be randomly assigned to either twice-weekly D-STORM training plus their usual diabetes care, or usual care alone, for 12 weeks. The main outcome measured is change in HbA1c (a blood test reflecting average blood sugar over 3 months). Body composition, walking capacity, blood pressure, heart rate, and quality of life will also be measured.
The D-STORM trial is a 2-arm parallel randomised controlled trial conducted at Hospital Sultan Al-Abdullah (HASA), Puncak Alam, Selangor, Malaysia. Adults aged 18 to 65 years with Type 2 diabetes mellitus (HbA1c 6.5% to 13.0%) who are not on insulin therapy will be recruited and randomly allocated 1:1 to the D-STORM intervention arm or the usual care arm.
The D-STORM programme consists of 6 compound resistance exercises performed twice weekly on non-consecutive days for 12 weeks, at 60-80% of one-repetition maximum (1RM), 2 working sets per exercise, using the double progression model with sets terminated at 1-3 repetitions in reserve (RIR).
The primary outcome is between-group difference in HbA1c (%) from baseline to 12 weeks, with a minimum clinically important difference of 1.0% absolute reduction. Secondary outcomes include body composition (bioelectrical impedance analysis; InBody 270), functional exercise capacity (Incremental Shuttle Walk Test), blood pressure, resting heart rate, and health-related quality of life (SF-36). Sample size: 124 participants (62 per arm), accounting for 10% dropout.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants perform the D-STORM resistance training programme twice weekly on non-consecutive days for 12 weeks, comprising 6 compound exercises at 60-80% 1RM, 2 working sets per exercise, terminated at 1-3 repetitions in reserve, using the double progression model. Participants also continue their usual diabetes care throughout.
Behavioral: D-STORM Resistance Training Programme
Participants receive standard diabetes care in accordance with the Malaysian Clinical Practice Guidelines for Type 2 Diabetes Management (6th Edition), including general physical activity recommendations of at least 150 minutes of moderate-intensity aerobic activity per week. No structured or supervised exercise is provided.
Other: usual care
Twice-weekly progressive resistance training comprising 6 compound exercises (upper body pull, upper body push, lower body push, lower body pull) at 60-80% 1RM, 2 working sets per exercise per session (minimum 4 sets per muscle group per week), 8-12 repetitions per set, terminated at 1-3 repetitions in reserve. Load is progressively increased using the double progression model. Total intervention duration is 12 weeks.
Participants receive standard diabetes care in accordance with the Malaysian Clinical Practice Guidelines for Type 2 Diabetes Management (6th Edition), including general physical activity recommendations of at least 150 minutes of moderate-intensity aerobic activity per week distributed over at least 3 days, with resistance exercise on a minimum of 2 non-consecutive days per week. No structured, supervised, or progressive training is provided.
Glycated Haemoglobin (HbA1c)
Between-group difference in HbA1c (%) from baseline to 12 weeks. The minimum clinically important difference is defined as a reduction of ≥1.0% absolute HbA1c. Measured by standardised laboratory assay at baseline (Visit 1) and post-intervention (Visit 7).
Time frame: Baseline to 12 weeks
Body Composition
Segmental body composition including skeletal muscle mass, fat mass, fat-free mass, and body fat percentage measured by bioelectrical impedance analysis (InBody 270) under standardised conditions.
Time frame: Baseline to 12 weeks
Functional Exercise Capacity
Assessed using the Incremental Shuttle Walk Test (ISWT), measuring the maximum distance walked under a progressively increasing pace protocol.
Time frame: Baseline to 12 weeks
Blood Pressure
Systolic and diastolic blood pressure (mmHg) measured at Visits 1, 3, 5, 7, and 9.
Time frame: Baseline to 12 weeks
Resting Heart Rate
Resting heart rate (bpm) measured at Visits 1, 3, 5, 7, and 9.
Time frame: Baseline to 12 weeks
Health-Related Quality of Life
Assessed using the SF-36 questionnaire at baseline and post-intervention (12 weeks).
Time frame: Baseline to 12 weeks
Exercise Self-Efficacy
Self-reported exercise self-efficacy measured by validated questionnaire at baseline and post-intervention (12 weeks).
Time frame: Baseline to 12 weeks
Plan to share: Yes — Individual participant data that underlie the results reported in the published article will be made available after de-identification, including text, tables, figures, and appendices.
Supporting information: Study protocol
Time frame: Beginning 6 months after publication, for a period of 5 years.
Access criteria: Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Sep 2027, 8 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 8 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universiti Teknologi Mara